Emmaus Life Sciences, Inc. (OTC: EMMA) announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.
Read More
License Permits Importation and Early Access to Patients Pending Marketing Authorization
Read More
2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate.
Amended and Restated Form 10-K Includes Complete Restated Financial Statements and Currently Dated, Unqualified Audit Report.
Read More
Emmaus Life Sciences, Inc. (OTC: EMMA) announced today that Endari has been included on the Preferred Drug List published on July 29, 2021, by Texas Health and Human Services (THHS).
Read More
Emmaus Life Sciences, Inc. announced today preliminary sales results for the six months ended June 30, 2021.
Read More